 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Benefits of Lowering Cholesterol Levels in Older Patients
15 May 2001 | Volume 134 Issue 10 | Page S4
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Benefits of Pravastatin on Cardiovascular Events and Mortality in Older Patients with Coronary Heart Disease Are Equal to or Exceed Those Seen in Younger Patients: Results from the LIPID Trial." It is in the 15 May 2001 issue of Annals of Internal Medicine (volume 134, pages 931-940). The authors are D Hunt, P Young, J Simes, W Hague, S Mann, D Owensby, G Lane, and A Tonkin, for the LIPID Investigators.
What is the problem and what is known about it so far?
Coronary heart disease is a major cause of death in middle-aged and older adults. Several factors, including a high blood cholesterol level, can increase a person's risk for this type of heart disease. Various diet and drug treatments can help lower cholesterol and reduce the risk for heart disease. For example, drug treatments that lower blood cholesterol levels can prevent heart attacks and deaths from coronary heart disease in middle-aged adults. How well these drug treatments work in older adults has not been clear, however.
Why did the researchers do this particular study?
To see whether pravastatin, a drug that lowers cholesterol levels, is more or less effective in preventing heart disease in people 65 years of age or older compared with people 31 to 64 years of age.
Who was studied?
The study included 3514 men and women 65 to 75 years of age and 5500 men and women 31 to 64 years of age. All had had a heart attack or severe chest pain from heart disease. Some participants had cholesterol levels that were in the normal range, but the average cholesterol level among participants was high.
How was the study done?
The researchers randomly assigned participants to receive either 40 mg of pravastatin daily or placebo pills. The placebo looked like pravastatin but did not contain any active ingredients. Participants were then followed for 6 years.
What did the researchers find?
Compared with placebo, pravastatin lowered cholesterol levels and prevented bad outcomes in both older and younger participants. For every 1000 older patients treated during the 6-year study, pravastatin prevented 45 deaths and 133 major coronary events, including heart attacks, strokes, severe chest pain episodes, and heart surgeries. For every 1000 younger patients, pravastatin prevented 22 deaths and 107 major coronary events over 6 years. Both older and younger participants were able to take pravastatin without frequent or severe side effects.
What were the limitations of the study?
This study was originally designed to see whether pravastatin would help people 31 to 75 years of age who already had heart disease. The decision to see whether the benefits of pravastatin were similar in older and younger participants was made after the study was completed; the findings may be less reliable because the study was not primarily designed to answer this question.
What are the implications of the study?
Pravastatin prevents deaths and other major heart- and circulation-related problems in both older and younger people with known heart disease and average or high cholesterol levels. The potential benefits of treatment over 6 years are higher for older than for younger people, mainly because older people have greater risks for heart and circulation problems to begin with.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  J. M. Gill and Yingxia Chen Quality of Lipid Management in Outpatient Care: A National Study Using Electronic Health Records American Journal of Medical Quality, September 1, 2008; 23(5): 375 - 381. [Abstract] [PDF]
|
|
|
|
 |
|
 M. W. Medina, F. Gao, W. Ruan, J. I. Rotter, and R. M. Krauss Alternative Splicing of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Is Associated With Plasma Low-Density Lipoprotein Cholesterol Response to Simvastatin Circulation, July 22, 2008; 118(4): 355 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Krauss, L. M. Mangravite, J. D. Smith, M. W. Medina, D. Wang, X. Guo, M. J. Rieder, J. A. Simon, S. B. Hulley, D. Waters, et al. Variation in the 3-Hydroxyl-3-Methylglutaryl Coenzyme A Reductase Gene Is Associated With Racial Differences in Low-Density Lipoprotein Cholesterol Response to Simvastatin Treatment Circulation, March 25, 2008; 117(12): 1537 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Afilalo, G. Duque, R. Steele, J. W. Jukema, A. J.M. de Craen, and M. J. Eisenberg Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 37 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. P. Roberts, E. Guallar, and A. Rodriguez Efficacy and Safety of Statin Monotherapy in Older Adults: A Meta-Analysis J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 879 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. Alexander, L. K. Newby, P. W. Armstrong, C. P. Cannon, W. B. Gibler, M. W. Rich, F. Van de Werf, H. D. White, W. D. Weaver, M. D. Naylor, et al. Acute Coronary Care in the Elderly, Part II: ST-Segment-Elevation Myocardial Infarction: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology Circulation, May 15, 2007; 115(19): 2570 - 2589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bonovas and N. M. Sitaras Does pravastatin promote cancer in elderly patients? A meta-analysis Can. Med. Assoc. J., February 27, 2007; 176(5): 649 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bonovas, K. Filioussi, N. Tsavaris, and N. M. Sitaras Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials J. Clin. Oncol., October 20, 2006; 24(30): 4808 - 4817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Ray, R. G. Bach, C. P. Cannon, R. Cairns, A. J. Kirtane, S. D. Wiviott, C. H. McCabe, E. Braunwald, C. M. Gibson, and for the PROVE IT-TIMI 22 Investigators Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS Eur. Heart J., October 1, 2006; 27(19): 2310 - 2316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Tovar and D. B. Schering Management of Dyslipidemia in Special Populations Journal of Pharmacy Practice, April 1, 2006; 19(2): 63 - 78. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Bates, J. Y. Choi, P. W. Duncan, J. J. Glasberg, G. D. Graham, R. C. Katz, K. Lamberty, D. Reker, and R. Zorowitz Veterans Affairs/Department of Defense Clinical Practice Guideline for the Management of Adult Stroke Rehabilitation Care: Executive Summary Stroke, September 1, 2005; 36(9): 2049 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A Lawlor, P. Whincup, J. R Emberson, K. Rees, M. Walker, and S. Ebrahim The challenge of secondary prevention for coronary heart disease in older patients: findings from the British Women's Heart and Health Study and the British Regional Heart Study Fam. Pract., October 1, 2004; 21(5): 582 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Goldstein, K. Murao, H. Imachi, T. Ishida, and N. C. W. Wong Lipid-Altering Drugs: Decreasing Cardiovascular Disease at the Expense of Increasing Cancer? Cancer Res., September 15, 2004; 64(18): 6831 - 6832. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Higashi, P. G. Shekelle, D. H. Solomon, E. L. Knight, C. Roth, J. T. Chang, C. J. Kamberg, C. H. MacLean, R. T. Young, J. Adams, et al. The Quality of Pharmacologic Care for Vulnerable Older Patients Ann Intern Med, May 4, 2004; 140(9): 714 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A Dornbrook-Lavender, M. T Roth, and J. A Pieper Secondary Prevention of Coronary Heart Disease in the Elderly Ann. Pharmacother., December 1, 2003; 37(12): 1867 - 1876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Safford, L. Eaton, G. Hawley, M. Brimacombe, M. Rajan, H. Li, and L. Pogach Disparities in Use of Lipid-Lowering Medications Among People With Type 2 Diabetes Mellitus Arch Intern Med, April 28, 2003; 163(8): 922 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Allen Maycock, J. B. Muhlestein, B. D. Horne, J. F. Carlquist, T. L. Bair, R. R. Pearson, Q. Li, J. L. Anderson, and Intermountain Heart Collaborative Study Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients J. Am. Coll. Cardiol., November 20, 2002; 40(10): 1777 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. N. B. Merz, G. A. Mensah, V. Fuster, P. Greenland, and P. D. Thompson Task Force #5--the role of cardiovascular specialists as leaders in prevention: from training to champion J. Am. Coll. Cardiol., August 21, 2002; 40(4): 641 - 649. [Full Text] [PDF]
|
|
|
|
|
|
D. O. Fedder, C. E. Koro, G. J. L'Italien, A. M. Gotto Jr, and L. H. Kuller Primary Prevention Lipid-Lowering Drug Therapy * Response Circulation, August 13, 2002; 106 (7): e35 - e36. [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Evans The gifts reserved for age Int. J. Epidemiol., August 1, 2002; 31(4): 792 - 795. [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Benner, R. J. Glynn, H. Mogun, P. J. Neumann, M. C. Weinstein, and J. Avorn Long-term Persistence in Use of Statin Therapy in Elderly Patients JAMA, July 24, 2002; 288(4): 455 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. B. Applegate Elderly Patients' Adherence to Statin Therapy JAMA, July 24, 2002; 288(4): 495 - 497. [Full Text] [PDF]
|
|
|
|
|
|
H. Iwata, T. Aoyama, and M. Kami Effects of Pravastatin in the Elderly Ann Intern Med, June 4, 2002; 136(11): W2 - W2. [Full Text] [PDF]
|
|
|
|
|
|
J. Z. Ayanian, M. B. Landrum, and B. J. McNeil Use of Cholesterol-Lowering Therapy by Elderly Adults After Myocardial Infarction Arch Intern Med, May 13, 2002; 162(9): 1013 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Faergeman Estimation and reduction of cardiovascular risk in old people Eur. Heart J., February 2, 2002; 23(4): 261 - 263. [Full Text] [PDF]
|
|
|
|
|
|
J. Avorn Improving Drug Use in Elderly Patients: Getting to the Next Level JAMA, December 12, 2001; 286(22): 2866 - 2868. [Full Text] [PDF]
|
|
|
|
 |
|
 Pravastatin for Patients 75 and Younger Journal Watch Cardiology, July 20, 2001; 2001(720): 5 - 5. [Full Text]
|
|
|
|
 |
|
 Lipid Lowering Is Beneficial in Elders with Coronary Disease Journal Watch Women's Health, June 6, 2001; 2001(606): 9 - 9. [Full Text]
|
|
|
|
 |
|
 Lipid Lowering in Older Patients Journal Watch (General), June 1, 2001; 2001(601): 7 - 7. [Full Text]
|
|
|
|
|
|
Lipid Lowering Is Beneficial in Older Patients with Coronary Disease Journal Watch (General), May 25, 2001; 2001(525): 6 - 6. [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
